Q1 Earnings Estimate for Teleflex Issued By Wolfe Research

Teleflex Incorporated (NYSE:TFX) – Equities research analysts at Wolfe Research issued their Q1 2026 earnings estimates for shares of Teleflex in a research note issued on Wednesday, March 4th. Wolfe Research analyst M. Polark forecasts that the medical technology company will post earnings of $1.33 per share for the quarter. The consensus estimate for Teleflex’s current full-year earnings is $13.98 per share. Wolfe Research also issued estimates for Teleflex’s Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $2.48 EPS, Q4 2026 earnings at $3.21 EPS, FY2026 earnings at $8.25 EPS, Q1 2027 earnings at $2.60 EPS, Q2 2027 earnings at $2.90 EPS, Q3 2027 earnings at $3.11 EPS, Q4 2027 earnings at $3.61 EPS, FY2027 earnings at $12.19 EPS, FY2028 earnings at $13.71 EPS, FY2029 earnings at $15.36 EPS and FY2030 earnings at $17.14 EPS.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The company had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $912.57 million. During the same period in the prior year, the business posted $3.89 EPS. The company’s quarterly revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

Other research analysts have also recently issued reports about the company. Needham & Company LLC raised their price objective on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company increased their price target on shares of Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a report on Friday, February 27th. Wall Street Zen lowered shares of Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Monday, December 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Teleflex from $115.00 to $125.00 and gave the stock a “sector perform” rating in a research note on Friday, February 27th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $140.83.

Teleflex Stock Performance

Shares of TFX opened at $113.65 on Monday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.01 and a current ratio of 2.54. The stock has a 50-day moving average of $110.97 and a two-hundred day moving average of $118.56. The stock has a market cap of $5.02 billion, a P/E ratio of -5.53, a P/E/G ratio of 0.71 and a beta of 0.87. Teleflex has a one year low of $100.18 and a one year high of $143.32.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Friday, March 6th will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.2%. Teleflex’s dividend payout ratio is -6.62%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TFX. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Teleflex by 57.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 77 shares in the last quarter. Banque Cantonale Vaudoise raised its holdings in Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares during the period. Hantz Financial Services Inc. boosted its position in Teleflex by 40.5% during the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock worth $48,000 after purchasing an additional 113 shares in the last quarter. UMB Bank n.a. grew its holdings in Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares during the period. Finally, Maryland State Retirement & Pension System increased its position in shares of Teleflex by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after buying an additional 129 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Key Headlines Impacting Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Wolfe Research projects multi-year earnings recovery and growth for Teleflex, forecasting FY2027 EPS of $12.19 and continued expansion to $17.14 by FY2030 — a constructive long-term earnings trajectory if Teleflex executes. Wolfe Research model summary
• Neutral Sentiment: Wolfe issued detailed quarterly estimates (Q1–Q4 2026 and Q1–Q4 2027) to update models; these provide a clearer roadmap for quarterly cadence but do not by themselves change fundamentals. Analysts’ granularity may help set expectations ahead of upcoming quarters. Research note
• Negative Sentiment: Near-term concern: Wolfe’s FY2026 EPS of $8.25 sits well below the consensus cited in the filings (~$13.98) and contrasts with Teleflex’s prior FY2026 guidance (roughly $6.25–$6.55), highlighting forecast dispersion and uncertainty. This follows Teleflex’s most recent quarter where revenue and EPS missed expectations (quarterly revenue down ~28.5% YoY and a sizable EPS shortfall), which is weighing on the stock. Earnings and guidance details

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.